MONTE ROSA THERAPEUTICS, INC.

MarketScreener Strategies Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:25:04 04/09/26 am AEST			5-day change	1st Jan Change
14.44 ^USD	+1.58%		+0.56%	-8.16%

24/08	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
24/08	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

MarketScreener Strategies

No results match your criteria

All News Broker Recommendations Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies

Filters

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Unlock them now!